RS Crum Inc’s AbbVie ABBV Stock Holding History

RS Crum Inc’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$482K	Hold	2,217	–	–	0.09%	61
2025 Q4	$507K	Sell	2,217 -100	-4%	-$22.8K	0.1%	58
2025 Q3	$536K	Hold	2,317	–	–	0.12%	53
2025 Q2	$430K	Hold	2,317	–	–	0.1%	60
2025 Q1	$485K	Buy	2,317 +37	+2%	+$7.19K	0.13%	54
2024 Q4	$405K	Buy	2,280 +100	+5%	+$18.4K	0.1%	62
2024 Q3	$431K	Sell	2,180 -1	-0%	-$187	0.1%	62
2024 Q2	$374K	Buy	2,181 +480	+28%	+$79.5K	0.1%	65
2024 Q1	$310K	Sell	1,701 -116	-6%	-$20K	0.08%	68
2023 Q4	$282K	Sell	1,817 -33	-2%	-$4.81K	0.09%	69
2023 Q3	$276K	Buy	1,850 +250	+16%	+$36.7K	0.1%	65
2023 Q2	$216K	Hold	1,600	–	–	0.08%	70
2023 Q1	$255K	Hold	1,600	–	–	0.1%	67
2022 Q4	$259K	Hold	1,600	–	–	0.12%	66
2022 Q3	$215K	Sell	1,600 -1,603	-50%	-$230K	0.11%	67
2022 Q2	$491K	Hold	3,203	–	–	0.25%	45
2022 Q1	$519K	Hold	3,203	–	–	0.29%	42
2021 Q4	$434K	Buy	+3,203	New	+$378K	0.24%	47

Other funds holding ABBV

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

RS Crum Inc's ABBV Position: Q1 2026 in Review

RS Crum Inc held its AbbVie (ABBV) position steady in Q1 2026 at 2,217 shares worth $482K. The position accounts for 0.09% of the portfolio, ranked #61.

RS Crum Inc first reported a position in ABBV in Q4 2021 and has held it in 18 quarters since. The position peaked at $536K in Q3 2025. 4,076 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

RS Crum Inc held 2,217 shares of AbbVie worth $482K as of Q1 2026.
RS Crum Inc left its AbbVie share count unchanged in Q1 2026.
AbbVie made up 0.09% of RS Crum Inc's portfolio in Q1 2026, its #61 holding.
RS Crum Inc first reported a position in AbbVie in Q4 2021 and has held it in 18 quarters since.
RS Crum Inc's AbbVie position peaked at $536K in Q3 2025.
4,076 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on RS Crum Inc's 13F filing for Q1 2026, filed 15 Apr 2026.